SXTC

China Sxt Pharmaceuticals, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website xtchina.com
Employees(FY) 78
ISIN VGG2161P1403

Performance

-20.65%

-17.53%

-50.84%

-70.37%

-91.94%

YTD

-82.12%

Profile

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

Advanced Technical Analysis

Technical Analysis of SXTC 2024-12-20

The stock indicators reflect a bearish sentiment, with the Moving Average Score at 10, Oscillators Score at 36, and a Technical Score of 23, indicating overall weakness in price momentum and suggesting caution for potential investors. The low scores across all categories highlight a lack of bullish signals in the current market environment.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of SXTC

Stock Rank

Recent News & Updates

2024-10-07 04:15
China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency(Globenewswire)
2023-10-26 04:05
China SXT Pharmaceuticals, Inc. Regained Compliance with Nasdaq's Minimum Bid Price Rule(Globenewswire)
2023-10-03 20:30
China SXT Pharmaceuticals Announces One-for-Twenty-five Reverse Stock Split(Globenewswire)
2023-08-01 18:03
China SXT Pharmaceuticals Full Year 2023 Earnings: US$0.89 loss per share (vs US$5.52 loss in FY 2022)(Yahoo Finance)
2023-05-09 20:00
China SXT Pharmaceuticals, Inc. Receives 180-day Extension from Nasdaq to Meet Minimum Bid Price Rule(Yahoo Finance)
2023-03-28 21:43
Insiders who placed huge bets on China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) earlier this year would be disappointed with the 12% drop(Yahoo Finance)
2022-11-06 19:00
China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency(Yahoo Finance)
2022-05-18 00:30
China SXT Pharmaceuticals, Inc. Announces 1 for 20 Reverse Share Split(Yahoo Finance)
2022-03-14 10:33
China SXT Pharmaceuticals, Inc. Enters into Securities Purchase Agreement to Issue a 6% Convertible Promissory Note in the Original Principal Amount of $2.8 Million(Yahoo Finance)
2022-01-19 23:30
Aegis Capital Corp. Acted as Sole Bookrunner on a $4.1 Million Underwritten Public Offering of Ordinary Shares, Inclusive of the Over-Allotment, for China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC).(Yahoo Finance)
2022-01-19 21:45
China SXT Pharmaceuticals, Inc. Announces Successful Closing of $4.1 Million Follow-on Underwritten Offering of Ordinary Shares and Pre-Funded Warrants With Simultaneous Exercise of the Over-Allotment(Yahoo Finance)
2022-01-17 18:46
China SXT Pharmaceuticals Shares Plunge On $3.5M Equity Raise Issued At Steep Discount(Yahoo Finance)
2022-01-17 17:47
China SXT Pharmaceuticals, Inc. Prices $3.5 Million Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares(Yahoo Finance)
2022-01-14 04:43
China SXT Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares(Yahoo Finance)
2022-01-14 01:00
China SXT Pharmaceuticals, Inc. Adds Newly Developed Kuihuapan and Zhudanfen Advanced TCMP Products, and Announces the Expected Continuous Growth of Its Production Capacity of Luxuejin(Yahoo Finance)
2021-12-15 19:00
China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency(Yahoo Finance)
2021-10-17 20:00
China SXT Pharmaceuticals, Inc. Obtained a New Pharmaceutical Manufacturing Permit and Passed Its GMP Compliance-Inspection(Yahoo Finance)
2021-02-18 19:00
China SXT Pharmaceuticals, Inc. Announces 1 for 4 Reverse Share Split(Yahoo Finance)
2020-11-26 07:16
Is China SXT Pharmaceuticals, Inc. (SXTC) A Good Stock To Buy?(Yahoo Finance)
2020-09-08 21:00
NASDAQ Granted China SXT Pharmaceuticals, Inc. 180-Day Extension to Regain Compliance with Bid Price Requirement(Yahoo Finance)
2020-05-29 03:08
Hedge Funds Warming Up To China SXT Pharmaceuticals, Inc. (SXTC)(Yahoo Finance)
2020-03-15 21:00
China SXT Pharmaceuticals, Inc. Announces That It Received a Grant Supported by City Government(Yahoo Finance)
2020-01-27 20:35
How Does China SXT Pharmaceuticals's (NASDAQ:SXTC) P/E Compare To Its Industry, After Its Big Share Price Gain?(Yahoo Finance)
2020-01-24 01:23
China SXT Pharmaceuticals, Inc. Announces Plans to Increase Production(Yahoo Finance)
2020-01-15 19:00
China SXT Pharmaceuticals, Inc. Announced Regulatory Approval of Its DNA Exam Laboratory(Yahoo Finance)
2020-01-02 21:30
China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency(Yahoo Finance)
2019-12-03 18:10
What Is China SXT Pharmaceuticals's (NASDAQ:SXTC) P/E Ratio After Its Share Price Tanked?(Yahoo Finance)
2019-11-13 22:30
Should You Worry About China SXT Pharmaceuticals, Inc.s (NASDAQ:SXTC) ROCE?(Yahoo Finance)
2019-09-10 19:00
China SXT Pharmaceuticals, Inc. Granted to Establish Taizhou Research Center for Advanced TCMP Engineering Techniques(Yahoo Finance)
2019-08-18 20:00
China SXT Pharmaceuticals, Inc. Announces Filing of Annual Report on Form 20-F for Year Ended March 31, 2019(Yahoo Finance)

Page 1 of 2

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.